Screener / SEC EDGAR /CIK 0001676725 /10-K filed Feb 17, 2026, compared with Feb 18, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

IDEAYA Biosciences, Inc. IDYA

Compare with peers Embed
The 10-K against last year's

267 changes: 34 added, 91 removed, 139 reworded, 3 quiet changes

10-K Feb 17, 2026 vs Feb 18, 2025

10-K 0001193125-26-054533 (Feb 17, 2026) vs 10-K 0000950170-25-022183 (Feb 18, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

574 paragraphs · 13 new · 152 reworded · 27 gone · 10-K Feb 17, 2026 against Feb 18, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 262 · 50% changed Every version of it
If the Servier License Agreement is terminated, we terminate the GSK Collaboration Agreement, or any program thereunder due to a material breach by GSK, we may have the right to assume commercialization efforts for darovasertib in territories outside the responsibility at our own expense for the development of the applicable product candidates. United States. Assumption of sole responsibility for further development commercialization of darovasertib in territories outside the United States will greatly increase our expenditures, and may mean we need to which could limit the size and scope of one or more of our programs, seek additional funding and/or choose to stop work altogether on one or more of the affected product candidates. This could result in a limited potential to generate future revenue profit from such product candidates, the commercialization of darovasertib in territories outside the United States, and our business could be materially and adversely affected.
Paragraph 245 · 47% changed Every version of it
Our organization is committed to a broad approach to precision medicine that seeks to maximize our integrated biomarker and small molecule drug discovery capabilities. Our current portfolio consists of multiple programs, extending across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. Together, these programs require significant capital investment. The directly targeted therapy programs are at various stages of preclinical and clinical development, and our synthetic lethality programs are in the target identification, validation, lead optimization, and clinical stages of development. We seek to maintain a process of prioritization and resource allocation to maintain an optimal balance between advancing and expanding our synthetic lethality and direct targeting programs. Because we have limited financial and managerial resources, we focus on specific product candidates, indications and discovery programs. As a result, we may forgo or delay pursuit of opportunities with other product candidates that could have had greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaborations, licenses and other similar arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.
Paragraph 156 · 47% changed Every version of it
There are also several risks associated with biomarker identification and validation. We, in collaboration with any diagnostic partners, may not be able to identify predictive biomarkers or pharmacodynamic biomarkers for one or more of our programs. We may not be able to validate potential biomarkers (e.g., certain genetic mutations) or their functional relevance preclinically in relevant in vitro or in vivo models. Data analytics and information from databases that we rely on for identifying or validating some of our biomarker-target relationships may not accurately reflect potential patient populations. Potential biomarkers, even if validated preclinically, may not be functionally effective or validated in human clinical trials.
Paragraph 516 · 46% changed Every version of it
The acquisition or licensing of intellectual property rights for pharmaceutical products is very competitive. If we seek to acquire or license additional intellectual property rights, we may face substantial competition from a number of more established companies, some of which have acknowledged strategies to license or acquire products, and many of which have more institutional experience and greater financial and other resources than we have. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities, as may other emerging companies taking similar or different approaches to product licenses and/or acquisitions. In addition, a number of established research-based pharmaceutical and biotechnology companies may acquire products in late stages of development to augment their internal product lines, which may provide those companies with an even greater competitive advantage. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us or may interfere with our acquisition or licensing of rights from others. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.
Paragraph 270 · 46% changed Every version of it
In addition, we currently and may in the future rely on foreign contract manufacturing organizations, or CMOs, contract research organizations, or CROs and other foreign organizations and companies that conduct manufacturing or research for us. Such foreign entities may be subject to U.S. legislation, sanctions, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material or have an adverse effect on our ability to secure significant commitments from governments to purchase our potential therapies. For example, in January 2024, there was Congressional activity, including on December 18, 2025, President Trump signed into law the introduction National Defense Authorization Act of 2026 (NDAA), which includes § 851 often referred to as “the BIOSECURE Act.” Under the BIOSECURE Act, U.S. government agencies cannot (1) buy or obtain biotechnology equipment or services provided by a “biotechnology company of concern” (BCC); (2) enter into, extend, or renew a contract with any entity using biotechnology equipment or services provided by a BCC; or (3) expend loan or grant funds for biotechnology equipment or services provided by a BCC, whether directly or through a loan or grant recipient. Congress has interpreted a BCC as an entity that is under the control of a foreign adversary and that poses a risk to national security based on its research or multiomic data collection (e.g., collection of genomic information). The BIOSECURE Act does not bar a U.S. company from all federal contracts or grants simply because it does business with a BCC. The restriction applies only when a federal contract or grant would procure covered biotechnology equipment or services—directly or indirectly—from a designated company. While the BIOSECURE Act has a grandfathering period of five years for existing contracts, and has carveouts for manufacture of drugs for supply under Medicaid and Medicare Part B, subject to the Secretary of Veteran Affairs’ discretion, the impact of the BIOSECURE Act (H.R. 7085) in on the House of Representatives biotechnology industry is uncertain. If the foreign CROs and a substantially similar Senate bill (S.3558). The BIOSECURE Act was passed CMOs we rely on become subject to trade restrictions, sanctions, increased tariffs or other regulatory requirements by the House of Representatives in September 2024. If these bills become law, U.S. government (including designation as a BCC under the BIOSECURE Act), or similar laws are passed, they would if the U.S. or Chinese government take retaliatory actions due to recent or increased tensions between the United States and China, it may have the potential to severely restrict the ability of U.S. biopharmaceutical companies like us to purchase services or products from, or otherwise collaborate with, certain Chinese biotechnology “biotechnology companies “of of concern” without losing the ability to contract with, or otherwise receive funding from, the U.S. government.
Paragraph 217 · 45% changed Every version of it
For IDE251, we are not aware of IDE574, Pfizer is evaluating a KAT6/7 dual inhibitor in a Phase 1 clinical trial in addition to KAT6A inhibitor prifetrastat (PF-07248144) in a Phase 3 clinical trial. Several other companies developing therapeutics directed to both KAT6 and KAT7; however, there are several companies also developing drugs directed to KAT6. Pfizer is developing a KAT6A inhibitor, designated as PF-07248144, in a KAT6 only, including Hengrui, Menarini and Olema, which are conducting Phase 1 trial. Menarini also recently initiated a Phase 1 study for a KAT6A inhibitor called MEN-2312. Olema Oncology received IND clearance for a KAT6A/B inhibitor in December 2024 trials. Additionally, Isosterix, Prelude, Qubit and is expected to begin a Phase 1 trial soon. Additionally, Isoterix and Qubit several others are developing preclinical KAT6A KAT6 inhibitors.
Paragraph 450 · 44% changed Every version of it
Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and access, marketing cost disclosure disclosure, drug price reporting and other transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally-mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their Some U.S. states have enacted legislation creating so-called prescription drug affordability boards, and other healthcare programs. Furthermore, there to date one state has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. These reforms could reduce the ultimate demand for our product candidates or put pressure on our product pricing. used its prescription drug
Paragraph 212 · 43% changed Every version of it
For IDE034, we are not aware of any other companies developing bi-specific ADCs targeting both B7H3 and PTK7, however many companies are developing mono-antigen ADCs targeting either B7H3 or PTK7. Merck, Hansoh/GSK, Medilink, and Minghui are evaluating B7-H3 B7H3 ADCs in Phase 3 clinical trials. Several other companies have B7-H3 B7H3 ADCs in earlier phases of clinical development, including Beigene, BeOne, Duality, GSK, Innovent, Mabwell, MacroGenics, MediLink, Mabwell and Minghui. MacroGenics. Furthermore, Genmab, Day One, Kelun, Kivu and Day One Lilly are evaluating PTK7 ADCs in Phase 1 studies, and Lilly is advancing a preclinical PTK7 ADC. studies.

MD&A

88 paragraphs · 21 new · 38 reworded · 64 gone · 10-K Feb 17, 2026 against Feb 18, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 30 · 49% changed
We have recognized revenue from our GSK Collaboration Agreement during the year ended December 31, 2024 and in prior years, related to both development and regulatory milestones as they were achieved and the performance obligations associated with the Agreement were completed. We completed all performance obligations related to the upfront payment under the GSK Collaboration Agreement as of December 31, 2023 for the Pol Theta and WRN programs. Future collaboration revenue recognized under In December 2025, GSK notified us of its intention to terminate the GSK Collaboration Agreement is related to milestone payments as they are earned. Collaboration, Option and License Agreement, dated June 15, 2020, which will be effective 90 days following the date of GSK’s notice, or March 9, 2026.
Paragraph 39 · 48% changed
We are focusing substantially all of our resources on the development of our product candidates. We expect our research and development expenses to increase substantially during the next few years, as we seek to initiate and/or advance clinical trials for our product candidates, complete our clinical program, pursue regulatory approval of our product candidates and prepare for a possible commercial launch. Predicting the timing or the cost to complete our clinical program or validation of our commercial manufacturing and supply processes is difficult and delays may occur because of many factors, including factors outside of our control. For example, if the FDA or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development. Furthermore, we are unable to predict when or if our product candidates will receive regulatory approval with any certainty.
Paragraph 73 · 46% changed
See For more information, see Note 5. Operating Leases, Note 6. Commitments and Contingencies, Note 7. Income Taxes and Note 10. Significant Agreements, each in the section titled “Summary of Significant Accounting Policies—Recent Accounting Pronouncements” in Note 2 to our financial statements included appearing elsewhere in this Annual Report on Form 10-K for additional information. 10-K.
Paragraph 74 · 46% changed
Adequate additional funding may not be available to us on acceptable terms or at all. See the section of this Annual Report on Form 10-K titled “Part I, Item 1A. – Risk Factors” for additional risks associated with our substantial capital requirements.
Paragraph 71 · 38% changed
A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will continue to require additional capital to meet operational needs and capital requirements associated with such operating plans. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments or engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials. We may also be required to sell or license to others rights to our product candidates in certain territories or indications that we would prefer to develop and commercialize ourselves.
Paragraph 87 · 37% changed
See the section titled “Summary of Significant Accounting Policies—Recent Accounting Pronouncements” in For more detail on our critical accounting policies, refer to Note 2 to our the financial statements included appearing elsewhere in this Annual Report on Form 10-K for additional information. 10-K.
Paragraph 27 · 36% changed
To date, we have not generated any revenue from product sales, and we do not expect to generate any revenue from product sales unless and until we are able to initiate a registrational clinical trial, obtain regulatory approval and commercialize one of our product candidates in the future. Our revenue consists exclusively of collaboration revenue under the Servier License Agreement for the year ended December 31, 2025 and the GSK Collaboration Agreement, Agreement for the year ended December 31, 2024, including amounts that are recognized related to previously received upfront payments, development and regulatory milestone payments and amounts due and payable to us for research and development services. The amount of revenue recognized related to the GSK Collaboration Agreement, including as related to the previously received upfront payment or to certain development milestone payments, may vary considerably by period and certain components thereof may generally decrease year-over-year as we satisfy remaining performance obligations, for example, relating to the Pol Theta and WRN R&D Services. Since December 31, 2023, we have fully recognized the contract liabilities related to the upfront payment and reimbursements for the research and development performance obligations under the GSK Collaboration Agreement. There are no remaining contract liabilities as of December 31, 2024 as we concluded all the research and development performance obligations under the GSK Collaboration Agreement. The future revenue recognition will be contingent on additional milestones earned, profit sharing and royalties on any net product sales under our collaborations. We expect that any revenue we recognize or generate under the GSK Collaboration Agreement will fluctuate from period to period due to period to period variability in milestone payments and other payments.
Paragraph 20 · 35% changed
Since our inception in June 2015, we have devoted substantially all of our resources to discovering and developing our product candidates. We have incurred significant operating losses to date and expect that our operating expenses will increase significantly as we advance our product candidates through preclinical and clinical development; seek regulatory approval, and prepare for, and, if approved, proceed to commercialization; acquire, discover, validate and develop additional product candidates; obtain, maintain, protect and enforce our intellectual property portfolio; and hire additional personnel. Certain For information about our specific program costs that contribute to our operating expenses have been and/or will be reimbursed by GSK pursuant to the GSK Collaboration Agreement, including 100% of costs we incur for research we perform in connection with the Pol Theta program and 80% of the aggregate program costs incurred by us and GSK for research each of us performs for the Werner Helicase program. We also incur costs in accordance with the Gilead CSCSA and Second CSCSA. Gilead bears internal or external costs incurred in connection with its supply of Trodelvy. We bear all internal and external costs and expenses associated with the conduct of the combination study. We also incur costs in accordance with the Merck CTCSA. Merck provides KEYTRUDA for the study at no cost to us. We bear all internal and external costs and expenses associated with the conduct of the study. We also entered into two in-licensing agreements for ADCs with topoisomerase-I-inhibitor-payloads to expenses, see Note 10. Significant Agreements.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors327 words changed in this paragraph; it is 46% similar to last year's version.
In addition, we currently and may in the future rely on foreign contract manufacturing organizations, or CMOs, contract research organizations, or CROs and other foreign organizations and companies that conduct manufacturing or research for us. Such foreign entities may be subject to U.S. legislation, sanctions, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material or have an adverse effect on our ability to secure significant commitments from governments to purchase our potential therapies. For example, in January 2024, there was Congressional activity, including on December 18, 2025, President Trump signed into law the introduction National Defense Authorization Act of 2026 (NDAA), which includes § 851 often referred to as “the BIOSECURE Act.” Under the BIOSECURE Act, U.S. government agencies cannot (1) buy or obtain biotechnology equipment or services provided by a “biotechnology company of concern” (BCC); (2) enter into, extend, or renew a contract with any entity using biotechnology equipment or services provided by a BCC; or (3) expend loan or grant funds for biotechnology equipment or services provided by a BCC, whether directly or through a loan or grant recipient. Congress has interpreted a BCC as an entity that is under the control of a foreign adversary and that poses a risk to national security based on its research or multiomic data collection (e.g., collection of genomic information). The BIOSECURE Act does not bar a U.S. company from all federal contracts or grants simply because it does business with a BCC. The restriction applies only when a federal contract or grant would procure covered biotechnology equipment or services—directly or indirectly—from a designated company. While the BIOSECURE Act has a grandfathering period of five years for existing contracts, and has carveouts for manufacture of drugs for supply under Medicaid and Medicare Part B, subject to the Secretary of Veteran Affairs’ discretion, the impact of the BIOSECURE Act (H.R. 7085) in on the House of Representatives biotechnology industry is uncertain. If the foreign CROs and a substantially similar Senate bill (S.3558). The BIOSECURE Act was passed CMOs we rely on become subject to trade restrictions, sanctions, increased tariffs or other regulatory requirements by the House of Representatives in September 2024. If these bills become law, U.S. government (including designation as a BCC under the BIOSECURE Act), or similar laws are passed, they would if the U.S. or Chinese government take retaliatory actions due to recent or increased tensions between the United States and China, it may have the potential to severely restrict the ability of U.S. biopharmaceutical companies like us to purchase services or products from, or otherwise collaborate with, certain Chinese biotechnology “biotechnology companies “of of concern” without losing the ability to contract with, or otherwise receive funding from, the U.S. government.

Source: Item 1A, 10-K 0001193125-26-054533 vs Item 1A, 10-K 0000950170-25-022183

MD&A198 words changed in this paragraph; it is 44% similar to last year's version.
To date, we have not generated any revenue from product sales, and we do not expect to generate any revenue from product sales unless and until we are able to initiate a registrational clinical trial, obtain regulatory approval and commercialize one of our product candidates in the future. Our revenue consists exclusively of collaboration revenue under the Servier License Agreement for the year ended December 31, 2025 and the GSK Collaboration Agreement, Agreement for the year ended December 31, 2024, including amounts that are recognized related to previously received upfront payments, development and regulatory milestone payments and amounts due and payable to us for research and development services. The amount of revenue recognized related to the GSK Collaboration Agreement, including as related to the previously received upfront payment or to certain development milestone payments, may vary considerably by period and certain components thereof may generally decrease year-over-year as we satisfy remaining performance obligations, for example, relating to the Pol Theta and WRN R&D Services. Since December 31, 2023, we have fully recognized the contract liabilities related to the upfront payment and reimbursements for the research and development performance obligations under the GSK Collaboration Agreement. There are no remaining contract liabilities as of December 31, 2024 as we concluded all the research and development performance obligations under the GSK Collaboration Agreement. The future revenue recognition will be contingent on additional milestones earned, profit sharing and royalties on any net product sales under our collaborations. We expect that any revenue we recognize or generate under the GSK Collaboration Agreement will fluctuate from period to period due to period to period variability in milestone payments and other payments.

Source: Item 7, 10-K 0001193125-26-054533 vs Item 7, 10-K 0000950170-25-022183

Accounting Policies122 words changed in this paragraph; it is 56% similar to last year's version.
The Company applies the five-step model to contracts when (1) parties have approved the contract and are committed to performing respective obligations, (2) the Company can identify each party’s rights regarding the goods or services to be transferred, (3) the Company can identify the payment terms for the goods or services to be transferred, (4) the contract has commercial substance, and (5) it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines the performance obligations by assessing whether each promised good or service is distinct. Goods or services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligations when (or as) the performance obligations are satisfied. The Company constrains its estimate of the transaction price up to the amount (the “variable consideration constraint”) that a significant reversal of recognized revenue is not probable.

Source: 10-K text, Note 2 – Summary of Significant Accounting Policies, 10-K 0001193125-26-054533 vs 10-K text, Note 2 – Summary of Significant Accounting Policies, 10-K 0000950170-25-022183

Legal Proceedings31 words changed in this paragraph; it is 92% similar to last year's version.
6. Commitments and Contingencies Contingencies From time to time, the Company may be involved in litigation related to claims that arise in the ordinary course of its business activities. The Company accrues for these matters when it is probable that future expenditures will be made and these expenditures can be reasonably estimated. As of December 31, 2024, 2025, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s financial position, results of operations or cash flows. Indemnification The Company enters into standard indemnification arrangements in the ordinary course of business with vendors, clinical trial sites and other parties. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. Accordingly, the Company has not recorded a liability related to such indemnification agreements as of December 31, 2025.

Source: Item 3, via Note 6 – Commitments and Contingencies, 10-K 0001193125-26-054533 vs Item 3, via Note 6 – Commitments and Contingencies, 10-K 0000950170-25-022183

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of IDYA's Risk Factors and MD&A, 10-K Feb 17, 2026 against 10-K Feb 18, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
To date, we have primarily financed our operations through the sale of equity securities and payments received under our collaboration and licensing agreements. We will be required to seek additional funding in the future and currently intend to
Read it in 10-K Feb 17, 2026 at sec.gov
AddedRisk Factors
We will need to successfully initiate and complete our own Phase 1 clinical trials and later-stage and pivotal clinical trials in order to obtain FDA or a comparable foreign regulatory body’s approval to market our product candidates. Carrying out clinical trials and the submission of regulatory filings is a complicated process. As an organization, we have limited
Read it in 10-K Feb 17, 2026 at sec.gov
AddedRisk Factors
As another example, the regulatory landscape related to clinical trials in the EU recently evolved. The EU CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. While the EU Clinical Trials Directive required a separate CTA to be submitted in each member state in which the clinical trial takes place,
Read it in 10-K Feb 17, 2026 at sec.gov
AddedRisk Factors
Aside from PARP inhibitors, such as Lynparza, Rubraca, Zejula and Talzenna, no synthetic lethality small molecule inhibitor therapeutics have been approved to date by the FDA or other comparable regulators. AEs in future clinical trials of our product candidates or in clinical trials of others developing similar products and the resulting publicity, as well as any other
Read it in 10-K Feb 17, 2026 at sec.gov
AddedRisk Factors
determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.
Read it in 10-K Feb 17, 2026 at sec.gov
AddedRisk Factors
programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our business, financial condition, results of operations and prospects.
Read it in 10-K Feb 17, 2026 at sec.gov
Show the other 67
AddedRisk Factors
Under the terms of the Servier License Agreement, we have limited ability to influence and control Servier’s commercialization efforts for darovasertib. If Servier does not perform in conformance with the terms and conditions of the Servier License Agreement, the commercialization of darovasertib in territories outside the United States could be adversely impacted. Any legal or equitable remedies that we may obtain in the event of Servier’s breach of the Servier License Agreement may not adequately compensate us for the losses caused by Servier.
Read it in 10-K Feb 17, 2026 at sec.gov
AddedRisk Factors
Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates or impair our competitive position. As the biotechnology industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third
Read it in 10-K Feb 17, 2026 at sec.gov
AddedRisk Factors
The One Big Beautiful Bill Act, which was enacted in July 2025, imposes significant reductions in the funding of the Medicaid program. Such reductions are expected to decrease the number of persons enrolled in Medicaid and reduce the services covered by Medicaid, which could adversely affect our sales of any product candidate that we commercialize.
Read it in 10-K Feb 17, 2026 at sec.gov
RemovedRisk Factors
In connection with the GSK Collaboration Agreement, if GSK terminates any development program under its collaborations with us, whether as a result of our inability to meet milestones or otherwise, any potential revenue from those collaborations will be significantly reduced or non-existent, and our results of operations and financial condition will be materially and adversely affected.
Read it in 10-K Feb 18, 2025 at sec.gov
RemovedRisk Factors
We have invested a significant portion of our time and financial resources in the development of multiple product candidates that are included in our strategic partnership and collaboration with GSK, under the GSK Collaboration Agreement entered into on June 15, 2020, or the GSK Collaboration Agreement. The programs currently included in the GSK Collaboration Agreement are the Pol Theta and WRN programs.
Read it in 10-K Feb 18, 2025 at sec.gov
RemovedRisk Factors
Under the GSK Collaboration Agreement, we will be eligible to receive from GSK future development and regulatory milestones of up to $475.0 million for the Pol Theta and $475.0 million for the WRN product, and commercial milestones of up to $475.0 million, with respect to the Pol Theta and WRN product. Additionally, we are entitled to receive 50% of U.S. net profits and tiered royalties on global non-U.S. net sales of WRN products by GSK, its affiliates and their sublicensees ranging from high single digit to sub-teen double digit percentages, subject to certain customary reductions. We are entitled to receive tiered royalties on global net sales of Pol Theta products by GSK, its affiliates and their sublicensees ranging from high single digit to sub-teen double digit percentages, subject to certain customary reductions. We have a right to opt-out of the 50% U.S. net profit share and corresponding development cost share for the WRN program, and would be eligible to receive tiered royalties on U.S. net sales of WRN products by GSK, its affiliates and their sublicensees at the same royalty rates as for global non-U.S. net sales thereafter, with potential positive economic adjustments based on the stage of the WRN program, as applicable, at the time of opt-out. There is no guarantee that we will be able to successfully continue to advance the Pol Theta and WRN programs and receive regulatory filing milestone payments related to any Pol Theta or WRN product. GSK may terminate the entire GSK Collaboration Agreement or any collaboration program on a target-by-target basis for any or no reason upon written notice to us after expiration of a defined notice period. The GSK Collaboration Agreement or any program under the GSK Collaboration Agreement may also be terminated by either party for the other party’s insolvency or certain uncured breaches. We may terminate the GSK Collaboration Agreement if GSK or any of its sublicensees or affiliates challenge certain of our patents. Depending on the timing of any such termination we may not be entitled to receive the option exercise fees, or potential milestone payments, as these payments terminate with termination of the GSK Collaboration Agreement.
Read it in 10-K Feb 18, 2025 at sec.gov
RemovedRisk Factors
•our cash expenditures could increase significantly if it is necessary for us to hire additional employees and allocate scarce resources to the development and commercialization of product candidates that were previously funded by GSK;
Read it in 10-K Feb 18, 2025 at sec.gov
RemovedRisk Factors
•we would bear all of the risks and costs related to the further development and commercialization of product candidates that were previously the subject of the GSK Collaboration Agreement, including the reimbursement of third parties; and
Read it in 10-K Feb 18, 2025 at sec.gov
RemovedRisk Factors
•in order to fund further development and commercialization, we may need to seek out and establish alternative collaboration arrangements with third-party collaboration partners; this may not be possible, or we may not be able to do so on terms which are acceptable to us, in which case it may be necessary for us to limit the size or scope of one or more of our programs or increase our expenditures and seek additional funding by other means.
Read it in 10-K Feb 18, 2025 at sec.gov
RemovedRisk Factors
but there is a tiered system extending the grace period for many in vitro diagnostic medical devices (depending on their risk classification) before they have to be fully compliant with the Regulation.
Read it in 10-K Feb 18, 2025 at sec.gov
RemovedRisk Factors
while our precision medicine target and biomarker discovery platform and our scientific and technical know-how give us a competitive advantage in this space, competition from many sources remains. Our competitors include larger and better funded biopharmaceutical, biotechnological and oncology therapeutics companies, as well as universities and other research institutions.
Read it in 10-K Feb 18, 2025 at sec.gov
RemovedRisk Factors
For BCG034, we are not aware of any other companies developing bispecific ADCs targeting both B7-H3 and PTK7; however, many companies are developing mono-antigen ADCs targeting either B7-H3 or PTK7. Merck and Hansoh are both
Read it in 10-K Feb 18, 2025 at sec.gov
RewordedRisk Factors
If these bills the foreign CROs and CMOs we rely on become law, subject to trade restrictions, sanctions, increased tariffs or similar laws are passed, they would other regulatory requirements by the U.S. government (including designation as a BCC under the BIOSECURE Act), or if the U.S. or Chinese government take retaliatory actions due to recent or increased tensions between the United States and China, it may have the potential to severely restrict the ability of U.S. biopharmaceutical companies like us to purchase services or products from, or otherwise collaborate with, certain Chinese biotechnology “biotechnology companies “of of concern” without losing the ability to contract with, or otherwise receive funding from, the U.S. government.
Read it in 10-K Feb 17, 2026 at sec.gov
RewordedRisk Factors
If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our business, financial condition, results of operations and prospects.
Read it in 10-K Feb 17, 2026 at sec.gov
RewordedRisk Factors
Furthermore, if any of our product candidates are approved and contract manufacturers fail to deliver the required commercial quantities of finished product on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent volumes and quality and on a timely basis, we would likely be unable to meet demand for our products and could lose potential revenue.
Read it in 10-K Feb 17, 2026 at sec.gov
RewordedRisk Factors
If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations.
Read it in 10-K Feb 17, 2026 at sec.gov
RewordedRisk Factors
As a result of our ceasing to be an emerging growth company and being deemed a “large accelerated filer” as of January 1, 2024, commencing with our Annual Report on Form 10-K for the year ending December 31, 2023, Additionally, our independent registered public accounting firm is required to formally attest to the effectiveness of our internal control over financial reporting pursuant to Section 404.
Read it in 10-K Feb 17, 2026 at sec.gov
RewordedRisk Factors
Our ability to raise additional funds will depend on financial, economic and other factors, including the ongoing effects geopolitical conflicts, health outbreaks, and/or banking sector volatility, and any worsening of the COVID-19 pandemic, the Ukraine-Russia conflict, the Israel-Hamas conflict, global business and closure of or liquidity issues at financial institutions, economic environment, many of which are beyond our control.
Read it in 10-K Feb 17, 2026 at sec.gov
RewordedRisk Factors
Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.
Read it in 10-K Feb 17, 2026 at sec.gov
RewordedRisk Factors
Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke approval of the therapy used in combination with our product candidates or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies.
Read it in 10-K Feb 17, 2026 at sec.gov
RewordedRisk Factors
Additionally, Immunocore is developing and commercializing has commercialized Tebentafusp, also known under its branded name as Kimmtrak, for the treatment of adult patients with HLA-A*02:01-positive HLA*A2(+), unresectable or MUM. iOnctura has initiated a Phase 2 trial for Roginolisib, an allosteric PI3K delta inhibitor, in 2L+ MUM. metastatic UM.
Read it in 10-K Feb 17, 2026 at sec.gov
RewordedRisk Factors
CMS has published the negotiated prices for the initial ten drugs, which went into effect in 2026, and the subsequent 15 drugs, which will first be effective in 2026, and has published the list of the subsequent 15 drugs that will be subject to negotiation, 2027, although the drug price negotiation program is currently subject to legal challenges.
Read it in 10-K Feb 17, 2026 at sec.gov
RewordedRisk Factors
Furthermore, certain of our product candidates may be co-administered with third-party approved or experimental therapies, therapies in our clinical trials, such as darovasertib with crizotinib in the combination arms of our Phase 1/2 clinical trial or IDE397 with PRMT5 inhibitors in the combination arms of our Phase 1/2 clinical trial. inhibitors.
Read it in 10-K Feb 17, 2026 at sec.gov
RewordedRisk Factors
The intellectual property laws and other statutory and contractual arrangements in the United States and other jurisdictions we depend upon may not provide sufficient protection in the future to prevent the infringement, use, violation or misappropriation of our patents, trademarks, data, technology and other intellectual property rights and products by others, and may not provide an adequate remedy if our intellectual property rights are infringed, misappropriated or otherwise violated by others.
Read it in 10-K Feb 17, 2026 at sec.gov
Quiet changesRisk Factors
In the future, we may also become dependent on other product candidates that we may develop or acquire; however, given the current stages of development for most of our product candidates, it may be several years, if at all, before we have demonstrated the safety and efficacy of a product candidate sufficient to support approval for commercialization.
Read it in 10-K Feb 17, 2026 at sec.gov
AddedMD&A
We are a precision medicine oncology company committed to the discovery, development and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates (ADCs), for molecularly defined solid tumor indications. Our clinical development strategy is to evaluate our product candidates in rational combinations, where appropriate, and earlier in the course of disease in the adjuvant and neoadjuvant settings, which we believe has the potential to maximize their impact. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Read it in 10-K Feb 17, 2026 at sec.gov
AddedMD&A
Darovasertib is an oral, potent and selective small molecule inhibitor of protein kinase C (PKC) and our most advanced clinical program. We are developing darovasertib for uveal melanoma (UM), a rare, aggressive form of ocular cancer in both the metastatic and pre-metastatic settings of UM, as described below.
Read it in 10-K Feb 17, 2026 at sec.gov
AddedMD&A
•Metastatic UM (mUM). We are evaluating darovasertib in combination with crizotinib, Pfizer’s oral c-MET inhibitor, in a potentially registration-enabling, Phase 2/3 trial (OptimUM-02) for human leukocyte antigen-A*02:01 negative (HLA*A2(-)), patients with first line (1L) mUM. We expect to report topline data, including progression free survival (PFS) data, from this trial in the first quarter of 2026. The data from OptimUM-02 may enable an accelerated approval filing in the United States. In December 2025, we completed full enrollment of 437 patients in OptimUM-02, and plan to submit overall survival (OS) data from these patients, when available, to support a full approval filing in this indication.
Read it in 10-K Feb 17, 2026 at sec.gov
AddedMD&A
We are also evaluating the combination of darovasertib and crizotinib in HLA*A2:01 positive (HLA*A2(+)), mUM patients in our ongoing, single-arm Phase 2 OptimUM-01 trial. We expect to complete enrollment of approximately 100 patients in this trial by the second quarter of 2026 with data used to support a potential future submission to the FDA to expand the labeled use for darovasertib and/or a national comprehensive cancer network (NCCN) compendia listing to enable use of the combination in these patients.
Read it in 10-K Feb 17, 2026 at sec.gov
AddedMD&A
•Neoadjuvant UM. We are also evaluating darovasertib as a monotherapy in the neoadjuvant setting of primary UM, where the goal of treatment is to prevent enucleation (surgical eye removal), preserve vision prior to and post-plaque brachytherapy and potentially delay or prevent progression to metastatic disease. In 2025, we initiated a randomized Phase 3 trial of darovasertib in the neoadjuvant setting (OptimUM-10), which will enroll approximately 450 patients across two cohorts of plaque brachytherapy-eligible (PB) and enucleation-eligible (EN) patients. We plan to complete enrollment in this trial by the first half of 2027.
Read it in 10-K Feb 17, 2026 at sec.gov
AddedMD&A
•Adjuvant UM. We plan to initiate a global Phase 3 combination trial (OptimUM-11) of darovasertib and crizotinib in the adjuvant setting of primary UM in the first half of 2026. The trial is expected to enroll approximately 450 patients with high to medium-high risk of metastasis, randomized 1:1 to the combination of darovasertib and crizotinib or placebo. The primary endpoint of this trial is relapse-free survival (RFS).
Read it in 10-K Feb 17, 2026 at sec.gov
AddedMD&A
In August 2025, we entered into an exclusive license agreement with Les Laboratoires Servier (Servier), for the development and commercialization of darovasertib outside of the United States. We received an upfront payment of $210.0 million and are eligible to receive up to $320.0 million in milestone payments, clinical trial cost sharing and clinical trial cost reimbursement, as well as double-digit royalties on net sales in all territories outside of the United States.
Read it in 10-K Feb 17, 2026 at sec.gov
AddedMD&A
•IDE849 is a potential first-in-class, DLL3 TOP1 ADC being evaluated by our partner, Hengrui Pharma, in a multi-site, open label Phase 1 clinical trial in China in patients with small-cell lung cancer (SCLC) and neuroendocrine carcinomas (NEC). We are currently conducting a global Phase 1 trial of IDE849 in SCLC, with the goal of initiating a monotherapy registrational trial in the second line/refractory setting (2L+) of SCLC and/or NEC by the end of 2026.
Read it in 10-K Feb 17, 2026 at sec.gov
AddedMD&A
•IDE034 is a potential first-in-class, B7H3/PTK7 bispecific TOP1 ADC. We received investigational new drug (IND) clearance from the FDA in the fourth quarter of 2025 and expect to achieve first-patient-in (FPI) in our Phase 1 dose escalation trial in the first quarter of 2026. Dosing of the first patient with IDE034 will trigger a $5.0 million milestone payment to Biocytogen, pursuant to our Option and License Agreement.
Read it in 10-K Feb 17, 2026 at sec.gov
AddedMD&A
•IDE161 is a potential first-in-class, oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor in a Phase 1 dose optimization trial to inform future combination studies with IDE849 and other TOP1-based ADCs where PARG inhibition may synergize with the payload to deepen responses. We plan to initiate a Phase 1 clinical combination trial of IDE161 with IDE849 in SCLC, NEC, and potentially other DLL3-overexpressing solid tumors in the second quarter of 2026. We may also evaluate clinical combinations of IDE161 with IDE034 (B7H3/PTK7) and potentially other TOP1 ADCs in collaboration with third parties.
Read it in 10-K Feb 17, 2026 at sec.gov
AddedMD&A
•IDE705 is a potential first-in-class, oral small molecule inhibitor of the helicase domain of Pol Theta that had been in a Phase 1 combination trial with niraparib, GSK’s small molecule inhibitor of PARP, in patients with BRCA+ or other HRD-positive tumors. In December 2025, GSK notified us of its intention to terminate the Agreement, which will be effective March 9, 2026. We plan to begin preclinical studies evaluating the potential of IDE705 to enhance the efficacy of TOP1 ADCs in solid tumors, as we are doing with IDE161, within our focus area of ADC/DDR combinations.
Read it in 10-K Feb 17, 2026 at sec.gov
RemovedMD&A
We are a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are most likely to benefit from these targeted therapies. Our small molecule drug discovery expertise includes discovery and development of small molecule therapeutics. We are applying these capabilities and approach to develop a robust pipeline in precision medicine oncology. Our clinical pipeline includes six potential first-in-class clinical-stage product candidates – darovasertib (PKC), IDE397 (MAT2A), IDE849(DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). We own or control all commercial rights of three of these product candidates: darovasertib, IDE397, and IDE161, and own or control all commercial rights outside of greater China for IDE849. We are also advancing several development candidates, including IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor for which we are targeting an investigational new drug, or IND, filing in mid-year 2025; IDE034, a potential first-in-class B7H3/PTK7 topoisomerase-I-inhibitor-payload bispecific antibody drug conjugate, or BsADC, program for which we are targeting an IND filing in the second half of 2025; and IDE251, a potential first-in-class KAT6/7 dual inhibitor program for which we are targeting an IND filing in the second half of 2025. We also have multiple earlier-stage preclinical programs. We have established selective, value-accretive collaborations with leading pharmaceutical companies to support our clinical development activities.
Read it in 10-K Feb 18, 2025 at sec.gov
RemovedMD&A
Darovasertib (IDE196) is our most advanced clinical-stage product candidate, which we in-licensed from Novartis. Darovasertib is a potent, selective small molecule inhibitor of protein kinase C, or PKC, which we are developing for genetically-defined cancers having GNAQ or GNA11 gene mutations. PKC is a protein kinase that functions downstream of the GTPases GNAQ and GNA11.
Read it in 10-K Feb 18, 2025 at sec.gov
RemovedMD&A
We have enrolled over 230 patients as of February 7, 2025, and have opened multiple clinical sites, including international sites, in our potential registration-enabling Phase 2/3 clinical trial, designated as IDE196-002. The purpose of the clinical trial is to evaluate darovasertib in combination with crizotinib, Pfizer’s investigational cMET inhibitor, in patients having metastatic uveal melanoma, or MUM, with human leukocyte antigen-, or HLA-A*02:01 negative, or HLA-A2(-), serotype, as part of the second Clinical Trial Collaboration and Supply Agreement, or Second Pfizer Agreement, with Pfizer.
Read it in 10-K Feb 18, 2025 at sec.gov
RemovedMD&A
In December 2024, we announced the recommendation of a move-forward dose and the completion of the Part 2a dose optimization for the potential registration-enabling Phase 2/3 trial evaluating the combination of darovasertib and crizotinib in the first-line, or 1L setting in patients with HLA-A2(-) MUM.
Read it in 10-K Feb 18, 2025 at sec.gov
RemovedMD&A
We are enrolling additional HLA-A*02:01 positive, or HLA-A2(+), patients as an independent clinical strategy to address HLA-A2(+) MUM patients, in our ongoing Phase 2 clinical trial, designated as IDE196-001.
Read it in 10-K Feb 18, 2025 at sec.gov
RemovedMD&A
We have enrolled 95 patients as of December 31, 2024, in our Phase 2 clinical trial, designated as IDE196-009, evaluating darovasertib as single-agent neoadjuvant and adjuvant therapy in patients having primary uveal melanoma, or UM, with ongoing enrollment and multiple clinical sites open. We are targeting a clinical data update in over 75 patients and regulatory update(s) in in the first half of 2025, including vision data in plaque brachytherapy patients.
Read it in 10-K Feb 18, 2025 at sec.gov
RemovedMD&A
In September 2024, we announced interim clinical data from the ongoing Phase 2 Company-sponsored trial and provided a regulatory update on a potential Phase 3 registration-enabling clinical trial in neoadjuvant UM patients based on a Type C meeting held with the U.S. Food and Drug Administration, or FDA. Based on the FDA meeting, we currently project approximately 400 patients will be randomized for treatment with darovasertib in the treatment arm or the control arm, with potential modifications pending further feedback from the FDA. We are currently finalizing the trial protocol for neoadjuvant UM and are targeting to initiate the study in the first half of 2025.
Read it in 10-K Feb 18, 2025 at sec.gov
RemovedMD&A
We are also supporting evaluation of darovasertib as single-agent neoadjuvant and adjuvant therapy in primary UM in an ongoing investigator-sponsored clinical trial, or IST, captioned as “Neoadjuvant / Adjuvant trial of Darovasertib in Ocular Melanoma,” or NADOM, led by St. Vincent’s Hospital in Sydney with the participation of Alfred Health and the Royal Victorian Eye and Ear Hospital in Melbourne.
Read it in 10-K Feb 18, 2025 at sec.gov
RemovedMD&A
In June 2024, we announced interim clinical data from the ongoing investigator-sponsored Phase 2 trial of darovasertib as neoadjuvant/adjuvant treatment in UM, which was included in an oral presentation at the American Society of Clinical Oncology, or ASCO, 2024 Annual Meeting, and preliminary clinical data from our Phase 2 trial of darovasertib for neoadjuvant UM.
Read it in 10-K Feb 18, 2025 at sec.gov
RemovedMD&A
We own or control all commercial rights in our darovasertib program in UM, including in MUM and in primary UM, subject to certain economic obligations pursuant to our exclusive, worldwide license to darovasertib with Novartis.
Read it in 10-K Feb 18, 2025 at sec.gov
RemovedMD&A
IDE397, our small molecule methionine adenosyltransferase 2a, or MAT2A, inhibitor, is being evaluated in a Phase 1/2 clinical trial. We have selected a move-forward Phase 2 expansion dose for IDE397 monotherapy, based on adverse event, or AE, profile and preliminary clinical efficacy observed, including multiple partial responses by RECIST 1. We are enrolling patients with an initial focus in MTAP-deletion urothelial cancer, or UC, and non-small cell lung cancer, or NSCLC.
Read it in 10-K Feb 18, 2025 at sec.gov
RewordedMD&A
The net change in our operating assets and liabilities consisted primarily of cash inflows resulting from $8.3 a $2.6 million increase in lease liabilities, $2.7 million increase in accounts payable and $10.8 $10.4 million increase in accrued and other liabilities due to CRO fees paid to CROs, CMOs and consultants in support of research and manufacturing activities, partially offset by cash outflows of $6.2 resulting from a $7.8 million increase in prepaid and other assets and $1.4 $6.0 million increase in lease liabilities. contract assets related to the Servier License Agreement.
Read it in 10-K Feb 17, 2026 at sec.gov
RewordedMD&A
The increase in research and development expenses was primarily due to $75.0 million upfront payment under the Hengrui Pharma License Agreement for IDE849, $6.5 million in upfront and option exercise fees under the Biocytogen Option and License Agreement for IDE034, increases of $64.1 $74.1 million in fees paid to CROs, CMOs and consultants related to the advancement of our lead product candidates through preclinical and clinical studies, $15.6 $12.7 million in personnel-related expenses, including salaries, benefits and stock-based compensation, to support our growth, and $4.0 $8.2 million in costs for laboratory supplies, facilities and information technology costs to support our research and development programs.
Read it in 10-K Feb 17, 2026 at sec.gov
RewordedMD&A
Net cash used in provided by investing activities was $502.6 $70.0 million for the year ended December 31, 2024, 2025, which consisted primarily of $1.2 $680.2 million provided by maturities of marketable securities, offset by $607.9 billion used to purchase marketable securities and $3.9 $2.4 million used to purchase property and equipment, partially offset by $692.6 million provided by maturities of marketable securities. equipment.
Read it in 10-K Feb 17, 2026 at sec.gov
RewordedMD&A
See the section titled “Summary of Significant Accounting Policies—Recent Accounting Pronouncements” in For more detail on our critical accounting policies, refer to Note 2 to our the financial statements included appearing elsewhere in this Annual Report on Form 10-K for additional information. 10-K.
Read it in 10-K Feb 17, 2026 at sec.gov
RewordedMD&A
Net cash provided by financing activities was $677.6 $29.8 million for the year ended December 31, 2024, 2025, which consisted primarily of $274.4 million of net proceeds from our follow-on offering, $9.4 million of proceeds from issuance of pre-funded warrants, $379.9 $24.9 million of proceeds from ATM offering, $12.5 $3.4 million of proceeds from exercise of common stock options and $1.4 $1.5 million of proceeds from ESPP purchase. purchases.
Read it in 10-K Feb 17, 2026 at sec.gov
RewordedMD&A
See the section titled “Summary of Significant Accounting Policies—Recent Accounting Pronouncements” in Note 2 to our the financial statements included elsewhere in this Annual Report on Form 10-K for additional information. a description of recent accounting pronouncements that are applicable to our business and may potentially have an impact on our financial position and results of operations.
Read it in 10-K Feb 17, 2026 at sec.gov
RewordedMD&A
Darovasertib $ 98,071 $ 55,335 $ 25,829 IDE397(2) IDE397 14,662 16,629 11,985 IDE161 7,598 9,743 7,104 IDE849 11,457 75,000 Personnel related and stock-based compensation 67,192 54,543 38,948 Other research and development expenses (3): 158,423 45,642 expenses(2) 115,724 83,423 Total research and development expenses $ 314,704 $ 294,673 $ 129,508
Read it in 10-K Feb 17, 2026 at sec.gov
RewordedMD&A
Our revenue consists exclusively of collaboration revenue under the Servier License Agreement for the year ended December 31, 2025 and the GSK Collaboration Agreement, Agreement for the year ended December 31, 2024, including amounts that are recognized related to previously received upfront payments, development and regulatory milestone payments and amounts due and payable to us for research and development services.
Read it in 10-K Feb 17, 2026 at sec.gov
RewordedMD&A
Our non-cash charges consisted of $34.7 million in stock-based compensation, $2.4 million in depreciation and $1.4 million of the amortization of right of use assets, partially offset by $23.2 million accretion of discounts on marketable securities.
Read it in 10-K Feb 17, 2026 at sec.gov
RewordedMD&A
For example, if the FDA or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development.
Read it in 10-K Feb 17, 2026 at sec.gov
RewordedMD&A
Interest income increased decreased by $31.0 $6.9 million, or 145%, 13%, during the year ended December 31, 2024 2025 compared to the year ended December 31, 2023, 2024, primarily due to higher lower interest rates and investment balances. rates.
Read it in 10-K Feb 17, 2026 at sec.gov
RewordedMD&A
During the year ended December 31, 2024, pursuant to the January 2024 Sales Agreement, 2025, we sold an aggregate of 4,066,866 984,000 shares of our common stock for aggregate net proceeds of $164.0 $25.0 million at a weighted average sales price of approximately $41.28 $26.00 per share under the at-the-market offering pursuant to the January 2024 Sales Agreement with Jefferies as sales agent.
Read it in 10-K Feb 17, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/IDYA/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.